ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 307

Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches

Helena Andersson1, Ivar Sjaastad2, Thomas Schwartz2, Torhild Garen3, T. Mogens Aalokken4 and Øyvind Molberg1, 1Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway, 2Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, 3Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Department of Radiology, Oslo University Hospital, Oslo, Norway

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: interstitial lung disease, Myositis and pulmonary complications

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Pulmonary hypertension (PH) is a feared complication of the anti-synthetase syndrome (ASS) and has previously been reported to occur in 8% of the patients [1]. Prognosis is currently poor, but may be improved by earlier referral to diagnostic right heart catheterization (RHC) and therapeutic interventions. Data on non-invasive screening approaches for PH in ASS are limited. Here, the aim was to test the utility of four different and complementary PH screening approaches.

Methods:

In September 2011, 68/70 living ASS patients from the Oslo University Hospital ASS cohort were included in a cross-sectional study where pulmonary function tests (PFT), Echocardiography (Echo) and HRCT of the lungs were performed. In addition, medical reports from six dead patients with confirmed PH by RHC were analyzed. Arbitrary cut-off values for PH suspicion were defined as follows; (1) DLCO < 50 % of expected value, (2) a ratio between FVC% and DLCO%  >1.6, (3) Arteria pulmonalis (A Pulm) diameter ≥ 30 mm on lung CT, (4) estimated mean pulmonary arterial pressure (mPAP) ≥ 45 mmHg by Echo. HRCT and Echo analysts were blinded to the participant’s clinical status. Chi-Square test was used to evaluate statistical significance, p<0.05.

Results:

Median disease duration for the 68 patients was 71 months (6-362) and 97 % of the patients had been diagnosed with interstitial lung disease. Median DLCO% was 62% (range12-87), median FVC /DLCO ratio was 1.33 (0.53-3.03) and the median estimated mPAP and pulmonary artery diameters were 23 mmHg (0-98) and 29 mm (20-45), respectively. Altogether, 16/74 patients had performed RHC, confirming PH in 11/16 patients.

Values below the arbitrary PH suspicion cut-offs were frequent, most frequent was increased diameter of  A Pulm, seen in 30/72 (42%) patients. Values suspicious of PH in DLCO, FVC/DLCO ratio, and estimated mPAP were seen in 34%, 28% and 17%, respectively. The correlations between the four variables and confirmed/not confirmed PH are seen in Table 1; Significant correlations were seen between all four variables and confirmed PH, most with the diameter of A Pulm.

Table 1;Correlations between different parameters and Pulmonary Artery Pressure

Parameters

Not confirmed  PH

 

Confirmed PH

p-value

A Pulm < 30 mm, n/N(%)

42/62  (68)

0/10  (0)

<0.001

A Pulm > 30 mm, n/N(%)

20/62  (32)

 10/10 (100)

mPAP <45mmHg,n/N(%)

58/62  (94)

2/10  (20)

<0.001

mPAP >45mmHg,n/N(%)

4/62  (6)

8/10  (80)

DLCO ≥ 50%, n/N (%)

45/60  (75)

1/10  (10)

<0.001

DLCO ≤ 50%, n/N (%)

15/60  (25)

9/10  (90)

FVC/DLCO <1.6 n/N (%)

46/60  (77)

4/10  (40)

<0.027

FVC/DLCO >1.6 n/N(%)

14/60  (23)

6/10  (60)

Conclusion:

Although a small number of patients with confirmed PH, this study shows significant correlation between all tested screening-tools for PH and confirmed PH. All patients (N=10) with confirmed PH had a diameter of A Pulm > 30 mm, and 8/10 had a mPAP of > 45mmHg, indicating these two methods as possible screeningtest for PH. Further studies on PH and it’s predictors are most warranted.


Disclosure: H. Andersson, None; I. Sjaastad, None; T. Schwartz, None; T. Garen, None; T. M. Aalokken, None; Molberg, None.

To cite this abstract in AMA style:

Andersson H, Sjaastad I, Schwartz T, Garen T, Aalokken TM, Molberg . Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/screening-for-pulmonary-hypertension-in-the-anti-synthetase-syndrome-utility-of-four-different-screening-approaches/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/screening-for-pulmonary-hypertension-in-the-anti-synthetase-syndrome-utility-of-four-different-screening-approaches/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology